Ascentage Pharma Group Inc.

This study is testing a new drug called APG-2575 in 40 people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor …

This study tests whether adding the experimental drug lisaftoclax to standard chemotherapy (azacitidine) helps people with newly diagnosed, higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 adults worldwide will be randomly assigned to receive e…

This early-phase study tests an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects, while al…

This study tests a new drug called lisaftoclax, given alone or with other medicines, for people whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The main goals are to check safety and find the best dose. About 682 adults will take part. T…

This study is testing two experimental drugs, APG-115 and APG-2575, in people with certain blood cancers (T-PLL or NHL) that have come back or stopped responding to treatment. The goal is to find safe doses and see if the drugs can control the disease. About 78 adults will take p…

This study tests a new drug, olverembatinib, combined with chemotherapy against standard targeted therapy plus chemo for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). About 350 adults will join this global trial. The goal is …

This phase 3 study tests whether adding the experimental drug APG-2575 (Lisaftoclax) to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia live longer. About 486 participants who cannot tolerate strong chemotherapy will receive either the combo or…

This study tests an experimental pill called HQP1351 in adults with chronic myeloid leukemia (CML) or a related blood cancer (Ph+ ALL) that has stopped responding to at least two standard treatments. The goal is to find the best dose and check how safe and effective the drug is. …

This study tests whether adding a new drug called lisaftoclax to standard BTK inhibitor therapy helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 400 adults who have been on a BTK inhibit…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This early-stage study is testing a new drug called APG-5918 to see if it is safe and can help people with anemia, a condition where the body lacks enough healthy red blood cells. The study includes both healthy volunteers and anemic patients, and will measure side effects, drug …

This study looks at how a damaged liver affects the way the body handles a single dose of the drug olverembatinib. Researchers will compare people with normal liver function to those with mild or moderate liver problems. The goal is to understand how the liver processes the drug,…